Best Topoisomerase Inhibitor for carcinoma, non-small-cell lung
3 Topoisomerase Inhibitor drugs indicated for carcinoma, non-small-cell lung, ranked by our independent rating. The current highest-rated is camptosar. Compare them with all treatments for carcinoma, non-small-cell lung or the full Topoisomerase Inhibitor class. Not medical advice — always consult a professional.
Top topoisomerase inhibitor for carcinoma, non-small-cell lung: 1. Camptosar · 2. Onivyde · 3. Irinotecan Hydrochloride
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Camptosar | 56/100 | Prescription | — | View → |
| 2 | Onivyde | Not yet rated | Prescription | — | View → |
| 3 | Irinotecan Hydrochloride | Not yet rated |
Full ranking · 3 drugs
Frequently asked
- What is the best topoisomerase inhibitor for carcinoma, non-small-cell lung?
- By our independent rating, camptosar currently ranks highest among Topoisomerase Inhibitor drugs used for carcinoma, non-small-cell lung. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which topoisomerase inhibitor drugs treat carcinoma, non-small-cell lung?
- pharmaranks lists 3 Topoisomerase Inhibitor products indicated for carcinoma, non-small-cell lung, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.